Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Cytotoxic chemotherapies may expose the immune system to high levels of tumor antigens and expand the CD8(+) T-cell response to include weak or subdominant antigens. Here, we evaluated the in vivo CTL response to tumor antigens using a murine mesothelioma tumor cell line transfected with a neotumor antigen, ovalbumin, that contains a known hierarchy of epitopes for MHC class I molecules. We show that as tumors progress, effector CTLs are generated in vivo that focus on the dominant epitope SIINFEKL, although a weak response was seen to one (KVVRFDKL) subdominant epitope. These CTLs did not prevent tumor growth. Cisplatin treatment slowed tumor growth, slightly improved in vivo SIINFEKL presentation to T cells and reduced SIINFEKL-CTL activity. However, the CTL response to KVVRFDKL was amplified, and a response to another subdominant epitope, NAIVFKGL, was revealed. Similarly, gemcitabine cured most mice, slightly enhanced SIINFEKL presentation, reduced SIINFEKL-CTL activity yet drove a significant CTL response to NAIVFKGL, but not KVVRFDKL. These NAIVFKGL-specific CTLs secreted IFNγ and proliferated in response to in vitro NAIVFKGL stimulation. IL-2 treatment during chemotherapy refocused the response to SIINFEKL and simultaneously degraded the cisplatin-driven subdominant CTL response. These data show that chemotherapy reveals weaker tumor antigens to the immune system, a response that could be rationally targeted. Furthermore, while integrating IL-2 into the chemotherapy re…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cisplatin can broaden the spectrum of tumor antigens in vivo, thereby facilitating the cytotoxic T-cell response [39].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [39]
Citations
Cites
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
IMMUNODOMINANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I–RESTRICTED T LYMPHOCYTE RESPONSES
Yewdell, J. W., & Bennink, J. R. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.51 · Cited by 944
Virus-Specific CD8+ T Cells in Primary and Secondary Influenza Pneumonia
Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L., & Doherty, P. C. (1998) · Immunity · doi:10.1016/s1074-7613(00)80573-7 · Cited by 674
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
Miller, S. D., Vanderlugt, C. L., Begolka, W. S., Pao, W., Yauch, R. L., Neville, K. L., Katz-Levy, Y., Carrizosa, A., & Kim, B. S. (1997) · Nature Medicine · doi:10.1038/nm1097-1133 · Cited by 565
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Self-citationDeterminant spreading and the dynamics of the autoimmune T-cell repertoire
Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M., & Gammon, G. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90163-f · Cited by 461
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Self-citationMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Research works printed but not linked: 4
- el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295–3301 · DOI · Paper page
- Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180:1471–1483 · DOI · Paper page
- Lipford GB, Hoffman M, Wagner H, Heeg K (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150:1212–1222 · DOI
- Grufman P, Wolpert EZ, Sandberg JK, Karre K (1999) T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol 29:2197–2204 · doi:10.1002/(sici)1521-4141(199907)29:07<2197::aid-immu2197>3.0.co;2-b
Cited by
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
“authors treated tumor-bearing mice with either two doses of CDDP or a PBS control and demonstrated that tumor-associated CD11c + dendritic cells from mice treated with CDDP had greater MHC class I expression than did the dendritic cells from control mice (14).”
BackgroundCombining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 231
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Moreover, cisplatin also upregulates MHC-I in antigen-presenting cells, such as DC cells [156].”
BackgroundAdaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Ma, J., Setton, J., Lee, N. Y., Riaz, N., & Powell, S. N. (2018) · Nature Communications · doi:10.1038/s41467-018-05228-y · Cited by 195
Targeting macrophages rescues age‐related immune deficiencies in C57 BL/6J geriatric mice
Jackaman, C., Radley‐Crabb, H. G., Soffe, Z., Shavlakadze, T., Grounds, M. D., & Nelson, D. J. (2013) · Aging Cell · doi:10.1111/acel.12062 · Cited by 162
Self-citationMetabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 153
Gebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 152
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 146
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Heeke, A. L., & Tan, A. R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09972-4 · Cited by 141
Fabian, K. P., Wolfson, B., & Hodge, J. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728018 · Cited by 143
Unexpected therapeutic effects of cisplatin
Raudenská, M., Balvan, J., Fojtů, M., Gumulec, J., & Masařík, M. (2019) · Metallomics · doi:10.1039/c9mt00049f · Cited by 115
Immunogenic Apoptotic Cell Death and Anticancer Immunity
Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., & Krysko, D. V. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_6 · Cited by 110
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Lohneis, P., Sinn, M., Bischoff, S., Jühling, A., Pelzer, U., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Oettle, H., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.016 · Cited by 95
Chemotherapy for Lung Cancer in the Era of Personalized Medicine
Lee, S. H. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0068 · Cited by 98
Targeting ATR in cancer medicine
Sundar, R., Brown, J. S., Garces, A. I., & Yap, T. A. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.05.002 · Cited by 85
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 87
Cai, Z., Chen, J., Yu, Z.-Z., Li, H., Liu, Z., Deng, D., Liu, J., Chen, C., Zhang, C., Ou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207155 · Cited by 86
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
Gravett, A. M., Trautwein, N., Stevanović, S., Dalgleish, A. G., & Copier, J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438107 · Cited by 69
King, R. J., Shukla, S. K., He, C., Vernucci, E., Thakur, R., Attri, K. S., Dasgupta, A., Chaika, N. V., Mulder, S. E., Abrego, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02132-6 · Cited by 75
Immunological off-target effects of standard treatments in gastrointestinal cancers
Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 64
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Zheng, H., Zeltsman, M., Zauderer, M. G., Eguchi, T., Vaghjiani, R. G., & Adusumilli, P. S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0052 · Cited by 61
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 62
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Jenzer, M., Keß, P., Nientiedt, C., Endris, V., Kippenberger, M., Leichsenring, J., Stögbauer, F., Haimes, J., Mishkin, S., Kudlow, B., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02393-x · Cited by 53
Genomic Instability in Multiple Myeloma
Alagpulinsa, D. A., Szalat, R. E., Poznansky, M. C., & Reis, R. J. S. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.006 · Cited by 58
Kong, S., Zhang, J., Wang, L., Li, W., Guo, H., Weng, Q., He, Q., Lou, H., Ding, L., & Yang, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217432 · Cited by 71
Li, Q., Xu, L., Zhu, J., Zhong, Y., Yang, J., Wang, J., & Tan, H. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7530794 · Cited by 66
Wakita, D., IWAI, T., Harada, S., Suzuki, M. M., Yamamoto, K., & Sugimoto, M. (2019) · Anticancer Research · doi:10.21873/anticanres.13281 · Cited by 49
Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 51
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 43
Fabian, K. P., Kowalczyk, J. T., Reynolds, S. T., & Hodge, J. W. (2022) · Cells · doi:10.3390/cells11233826 · Cited by 43
Jackaman, C., & Nelson, D. J. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.11.009 · Cited by 31
Self-citationImmune mechanisms and possible immune therapy in testicular germ cell tumours
Chovanec, M., Mardiak, J., & Mego, M. (2019) · Andrology · doi:10.1111/andr.12656 · Cited by 32
Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 32
IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice
Jackaman, C., Dye, D. E., & Nelson, D. J. (2014) · AGE · doi:10.1007/s11357-014-9655-y · Cited by 33
Self-citationCurrent trends of anticancer immunochemotherapy
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25396 · Cited by 32
Kim, H., Kim, J. H., Ryu, Y., Kim, D., Lee, S., Shin, J., Hong, S., Kim, K., Jung, D., Song, G., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.704 · Cited by 28
Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire
Darmon, A., Zhang, P., Marill, J., Anesary, N. M., SILVA, J. D., & Paris, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02615-w · Cited by 29
Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects
Wong, R. M. H., Ianculescu, I., Sharma, S. P., Gage, D. L., Olevsky, O. M., Kotova, S., Kostic, M. N., Grundfest, W. S., Hou, D., & Cameron, R. B. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0472tr · Cited by 26
Graham, P. T., Nowak, A. K., Cornwall, S. M. J., Larma, I., & Nelson, D. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969678 · Cited by 27
Self-citationByrne, K. T., Zhang, P., Steinberg, S. M., & Turk, M. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302139 · Cited by 21
Personalising Treatment for High-Grade Serous Ovarian Carcinoma
Cojocaru, E., Parkinson, C., & Brenton, J. D. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.05.008 · Cited by 23
Zhu, C., Zhai, T., Su, M., Pan, H., Tang, Q., Huang, B., Chi, X.-R., Li, N., Xie, L.-H., Qiu, S.-Q., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07341-9 · Cited by 22
Yi, C., Bian, D., Wang, J., Hu, S., Sun, L., Yan, Y., Wang, S., Shen, Z., Yu, H., Yang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57184-z · Cited by 22
Yin, W., Ma, S.-C., Dong, Z., Xu, M., & Mao, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310331 · Cited by 16
Jackaman, C., Gardner, J. K., Tomay, F., Spowart, J., Radley‐Crabb, H. G., Dye, D. E., Fox, S. A., Proksch, S., Metharom, P., Dhaliwal, S. S., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564452 · Cited by 20
Self-citationImpact of Immunotherapy after Resection of Pancreatic Cancer
Tran, T. B., Maker, V. K., & Maker, A. V. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.01.016 · Cited by 16
Li, X., Zhou, H., Huang, W., Wang, X., Meng, M., Hou, Z., Liao, L., Tang, W., Xie, Y., Wang, R., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1368 · Cited by 13
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
Pandey, P., Khan, F., Upadhyay, T. K., & Maqsood, R. (2023) · Molecules · doi:10.3390/molecules28020862 · Cited by 16
Immunotherapy for malignant mesothelioma: reality check
Thapa, B., Watkins, D. N., & John, T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1241149 · Cited by 17
Advanced T and Natural Killer Cell Therapy for Glioblastoma
Yoon, W., & Chung, D. (2023) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2022.0267 · Cited by 14
Dual Responsive Hybrid Nanoparticle for Tumor Chemotherapy Combined with Photothermal Therapy
Liu, Y., Wang, T., Gao, X., & Li, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.034 · Cited by 12
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11
“With respect to specific chemotherapeutic agents, cisplatin can broaden the spectrum of tumor antigens in vivo, thereby facilitating the cytotoxic T-cell response [39].”
BackgroundDing, K., Peng, Z., & Xu, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241249041 · Cited by 12
Yu, B., Han, Y., Fu, Q., Gao, F., Peng, J., Zheng, G., Zhang, P., Huang, J., & Zhang, J. (2023) · Journal of Cancer · doi:10.7150/jca.82985 · Cited by 14
A review of the importance of immune responses in luminal B breast cancer
Nelson, D. J., Clark, B., Munyard, K., Williams, V. M., Groth, D., Gill, J., Preston, H. S., & Chan, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1282590 · Cited by 13
Self-citationLin, A., Zhu, L., Jiang, A., Mou, W., Zhang, J., & Luo, P. (2022) · Disease Markers · doi:10.1155/2022/8766448 · Cited by 10
Kasi, A., Al‐Jumayli, M., Park, R., Baranda, J. C., & Sun, W. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0010 · Cited by 9
Zhang, X., Zheng, J., Niu, Y., Xue, C., Yu, Y., Tan, K., & Cui, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059331 · Cited by 10
Ge, Y., Liu, X., Xu, Y., Su, Y., Li, Y., & Wang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1485849 · Cited by 11
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00001-7 · Cited by 9
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241208 · Cited by 11
L’immunothérapie au service de la chimiothérapie, de nouvelles avancées
Hanoteau, A., Henin, C., & Moser, M. (2016) · médecine/sciences · doi:10.1051/medsci/20163204013 · Cited by 8
MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
Wu, L.-Q., Wang, X.-C., He, X., Li, Q., Hua, Q., Liu, R.-R., & Qiu, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868203 · Cited by 8
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
Sereno, M., Higuera, O., Castellanos, P. C., Falagán, S., Mielgo-Rubio, X., Trujillo-Reyes, J. C., & Couñago, F. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i12.1182 · Cited by 7
Harnessing Genomic Stress for Antitumor Immunity
Pu, C., Tao, S., Xu, J., & Huang, M. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8221 · Cited by 6
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
Sherif, A. M., Winerdal, M. E., & Winqvist, O. (2018) · Bladder Cancer · doi:10.3233/blc-170123 · Cited by 7
Liu, S., Li, X., Wu, C., Yao, L., Dong, H., Zhang, H., Wang, Y., Wang, M., & Xu, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002528 · Cited by 7
Li, Q., Zhaohui, Z., Yaping, X., Liu, Z., Zhentao, L., Wang, Q., Gu, Y., Liu, Y., Yin, W., Yi, F., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13771 · Cited by 5
Gan, Y.-X., Li, G., Ou, X., Wang, C., & Du, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.778643 · Cited by 5
Liu, J.-S., Liu, J., Xiao, Q., Li, X., Chen, J., & Liu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1119837 · Cited by 8
Fan, M., Ma, Y., Deng, G., Si, H., Jia, R., Wang, Z., & Dai, G. (2024) · Pancreatology · doi:10.1016/j.pan.2024.03.017 · Cited by 4
Xu, R., Zhou, J., Yang, J., Yu, Y., Wang, H., Zhang, Z., Yang, J., Zhang, G., & Liao, R. (2024) · BioScience Trends · doi:10.5582/bst.2024.01376 · Cited by 7
Alotaibi, F., Alshammari, K. M., Alotaibi, B. A., & Alsaab, H. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1280591 · Cited by 6
Zhong, H., Li, Y., Raza, F., Xie, J., Rong, R., Qiu, M., & Su, J. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01396 · Cited by 4
Yang, L. F., Tang, J., Chi, Y., Li, H., Zhang, M., Zhang, H., Ma, X., Cheng, J., & Gao, C. (2025) · Medical Oncology · doi:10.1007/s12032-025-02918-8 · Cited by 3
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 8
Impact of immunotherapy use in patients with stage IV pancreatic carcinoma
Guddati, A. K., Komiya, T., Patel, S. J., Sharma, N. R., & Powell, E. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-191 · Cited by 3
Dhandapani, H., Seetharaman, A., Jayakumar, H., Ganeshrajah, S., Singh, S. S., Rajkumar, T., & Ramanathan, P. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e59 · Cited by 2
HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors
Sun, Q., Zhu, Y., Zhao, D., Yang, L., Zhang, S., & Huang, C. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251356387 · Cited by 2
Çetin, B., Bilgetekin, İ., & Özet, A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.008 · Cited by 3
Asada, Y., Teramura, C., Wada, T., Machida, Y., Koshinuma, S., & Yamamoto, G. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4464 · Cited by 2
Combining Immunotherapies with Standard Therapies in the Treatment of Cancer
Pitt, J. M., Hannani, D., Vétizou, M., & Zitvogel, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17024-9 · Cited by 2
Harnessing Chlorella vulgaris-derived extracellular vesicles for potentiated cancer immunotherapy
Meng, F., Zhang, C. H. I., Ma, Y., Chen, S. Y., Chen, Q., Liang, X., Fan, Z., Yang, L., & Zhang, X. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124442 · Cited by 2
Hanamure, Y., Hayashi, T., Takaki, M., & Ito, K. (2019) · Toukeibu Gan · doi:10.5981/jjhnc.45.41 · Cited by 1
Advances in antitumor chemotherapy effects on immune function
Huang, D. J., & Liang, X. (2020) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0020
Heinhuis, K. M. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/371
Smith, J. P., Hont, A. B., & Bollard, C. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0176
Mazloomi, E., Jazani, N. H., Abbasian, V., & Shahabi, S. (2021) · Journal of Research in Applied and Basic Medical Sciences · doi:10.52547/rabms.7.2.76
Duong, L., Jackaman, C., & Nelson, D. J. (2024) · Ageing and Cancer Research & Treatment · doi:10.70401/acrt.2025.0012
Self-citationDarmon, A., Zhang, P., Marill, J., Mohamed Anesary, N., SILVA, J. D., & Paris, S. (2022) · Figshare · doi:10.6084/m9.figshare.20003358
Metadata
- Authors
- Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J.
- Affiliations
- Curtin University (AU)
- The University of Western Australia (AU)
- Corresponding author
- Nelson, Delia J.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2012-06-20
- Volume
- 61
- Issue
- 12
- Pages
- 2343-2356
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029427
- OpenAlex
- W2078500268
- Cited by
- 105
- References
- 47
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 16 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 6 · 2016: 6 · 2015: 1 · 2014: 4 · 2013: 5
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- University of Queensland
- Curtin University of Technology
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chemotherapy, tumor antigens, CD8+ cytotoxic T lymphocytes, subdominant epitopes, mesothelioma, ovalbumin, SIINFEKL, cisplatin, gemcitabine, interleukin-2, interferon-gamma, tumor immunology, cancer immunotherapy
- MeSH terms
- Gemcitabine, Animals, Epitopes, Antigens, Neoplasm, Antineoplastic Agents, Cisplatin, Cytotoxicity, Immunologic, Deoxycytidine, Female, Interferon-gamma, Interleukin-2, Mesothelioma, Mice, Inbred C57BL, Ovalbumin, T-Lymphocytes, Cytotoxic, Transfection, Histocompatibility Antigens Class I, Antigen Presentation, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.